Treatment News : Hormonal Contraception Not Linked to HIV Risk - by Reed Vreeland

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 23, 2012

Hormonal Contraception Not Linked to HIV Risk

by Reed Vreeland

A new analysis of data from a clinical trial conducted by the HIV Prevention Trials Network (HPTN) casts doubt on at least one study suggesting that women using hormonal contraception are at greater risk of acquiring HIV, according to a presentation by researchers at the International Microbicide Conference held April 15–18 in Sydney.

The finding that neither injectable nor oral hormonal contraceptives are themselves associated with an increased risk of acquiring HIV comes from a retrospective review of data from HPTN 035, a Phase II HIV prevention trial that evaluated the vaginal microbicides PRO 2000 and BufferGel. However, coupled with a diagnosis of either gonorrhea or Chlamydia, hormonal contraceptive use was associated with statistically significant greater risk of HIV infection in the analysis involving roughly 3,000 African women enrolled in the study between 2005 and 2008.

The analysis comes on the heels of the World Health Organization (WHO) announcing it will maintain its current guidance on the use of hormonal contraceptives, which do not restrict their use by women living with HIV or at high risk of HIV. The WHO said that although some studies—including one initially presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention last summer in Rome—have suggested a possible increased risk of HIV acquisition with the use of progesterone-only injectable contraception, the totality of data is inconclusive.

Originally presented at a conference in 2009, HPTN 035 found that PRO 2000 was 30 percent more effective than a placebo in preventing HIV, although this finding was not statistically significant. BufferGel had no protective effect against HIV in the study.

Search: hormonal, contraception, hptn 035, pro 2000, buffergel, microbicide, transmission, prevention, dep-provera, estradiol, hiv prevention trials network, international microbicide conference

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.